Vantage logo

Orphazyme tries its luck 

Despite missing pretty much all the endpoints of a registrational study, the Danish company insists that it has a chance of approval for a treatment for an incurable…

Vantage logo

Pharma news over the Christmas period

If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.

Vantage logo

Idera’s reinvention takes a hit

The company’s lead, tilsotolimod, is meant to turn cold tumours hot, but it was investors who became frosty last week in response to mid-stage clinical results.